AssesSment of Early deteCtion basEd oN liquiD Biopsy in Intracranial Tumors

Recruiting

• Conditions: Intracranial Tumors

• Registration Number: NCT05679089
• Lead Sponsor: Zhujiang Hospital

Brief Summary

ASCEND-BRAIN is a prospective, observational study aimed at early-detection of intracranial tumors by combined assays of cfDNA methylation and other biomarkers. The study will enroll approximately 358 participants including intracranial malignant tumors, patients with benign disorders of central nervous system and healthy participants.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-11-01
• Status Verified: 2022-12
• Study First Submitted: 2022-12-28
• Study First Submitted QC: 2022-12-28
• Last Update Submitted: 2022-12-28
• Study First Posted: 2023-01-10
• Last Update Posted: 2023-01-10
• Primary Completion: 2023-12-31
• Study Completion: 2024-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 358

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The sensitivity and specificity of a cfDNA methylation-based early detection model for intracranial tumors.	12 months

Secondary Outcome Measures

Name	Time	Method
The sensitivity and specificity of a cfDNA methylation-based early detection model for intracranial tumors of different grades(WHO I-IV) and mutant subtypes(IDH mutant/wild type).	12 months

Trial Locations

Locations (1)

Zhujiang Hospital; 🇨🇳 Guangzhou, Guangdong, China